Treats major depressive disorder (MDD). ANDA 74721, held by Lannett Co Inc. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 74721 (Doxepin Hydrochloride), held by Lannett Co Inc, was first approved by FDA on Dec 29, 1998, with 7 approved supplements and 0 published complete response letters.
Doxepin hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 1998 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxepin HydrochlorideEQ 10MG BASE/ML · concentrate;oral | Doxepin Hydrochloride | Rx |
| Jul 17, 2014 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 14, 2008 | Supplement 9Labeling | Approved | None posted |
| Jun 26, 2007 | Supplement 8Labeling | Approved | None posted |
| Jun 5, 2006 | Supplement 7Labeling | Approved | None posted |
| Aug 15, 2005 | Supplement 6Labeling | Approved | None posted |
| Apr 30, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Aug 30, 2000 | Supplement 2Labeling | Approved | None posted |
| Dec 29, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters